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Abstract
Background: Current genome-wide association studies (GWAS) are normally implemented in a univariate framework and
analyze different phenotypes in isolation. This univariate approach ignores the potential genetic correlation between
important disease traits. Hence this approach is difficult to detect pleiotropic genes, which may exist for obesity and
osteoporosis, two common diseases of major public health importance that are closely correlated genetically.
Principal Findings: To identify such pleiotropic genes and the key mechanistic links between the two diseases, we here
performed the first bivariate GWAS of obesity and osteoporosis. We searched for genes underlying co-variation of the
obesity phenotype, body mass index (BMI), with the osteoporosis risk phenotype, hip bone mineral density (BMD), scanning
,380,000 SNPs in 1,000 unrelated homogeneous Caucasians, including 499 males and 501 females. We identified in the
male subjects two SNPs in intron 1 of the SOX6 (SRY-box 6) gene, rs297325 and rs4756846, which were bivariately associated
with both BMI and hip BMD, achieving p values of 6.82610
27 and 1.47610
26, respectively. The two SNPs ranked at the top
in significance for bivariate association with BMI and hip BMD in the male subjects among all the ,380,000 SNPs examined
genome-wide. The two SNPs were replicated in a Framingham Heart Study (FHS) cohort containing 3,355 Caucasians (1,370
males and 1,985 females) from 975 families. In the FHS male subjects, the two SNPs achieved p values of 0.03 and 0.02,
respectively, for bivariate association with BMI and femoral neck BMD. Interestingly, SOX6 was previously found to be
essential to both cartilage formation/chondrogenesis and obesity-related insulin resistance, suggesting the gene’s dual role
in both bone and fat.
Conclusions: Our findings, together with the prior biological evidence, suggest the SOX6 gene’s importance in co-
regulation of obesity and osteoporosis.
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Introduction
Genome-wide association studies (GWAS) have now become a
major strategy for genetic dissection of human complex diseases/
traits. Through this strategy, novel genetic polymorphisms have
been successfully identified for many common diseases of public
health importance. A general trend for current GWAS is to collect
multiple phenotypes of interest from a single study population and
analyze these phenotypes separately in a univariate framework [1].
However, this strategy is limited by ignoring potential genetic
correlation between different traits analyzed and hence is difficult
to detect pleiotropic genes that are important to the pathogenesis
of many correlated human diseases.
An effective strategy to tackle the challenge of detecting
pleiotropic genes is to analyze potentially correlated disease
phenotypes simultaneously via a multivariate GWAS approach.
This approach takes advantage of covariance between multiple
study phenotypes and therefore may be more powerful for
detecting pleiotropic genes. In addition, analyzing multiple
phenotypes jointly can also alleviate multiple testing problem
caused by testing different traits separately. Motivated by the
above reasons, we here performed the first bivariate GWAS
analyzing simultaneously two correlated diseases of public health
significance, obesity and osteoporosis. Our study may set an
example for future ‘‘multivariate’’ GWAS of common human
diseases.
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6827Obesity is a disease of excessive storage of body fat resulting
from chronic imbalance between energy intake and consumption
[2]. It is a serious public health problem affecting ,65% of adult
US population [3] and incurring a direct cost of ,$100 billion per
year [4]. Obese people are more likely to develop other serious
diseases, such as diabetes, hypertension, and coronary heart
diseases [5,6]. A commonly used measure for quantifying the
severity of obesity is body mass index (BMI) that is defined as body
weight divided by the square of height.
Osteoporosis is another major public health problem, which is
characterized by excessive skeletal fragility and susceptibility to
low trauma fractures among the elderly [7]. Currently ,10 million
people in the US suffer from and another ,34 million are at high
risk for the disease [7]. It results in.1.5 million osteoporotic
fractures (OF) each year in the US [7] and incurs the country a
direct cost of ,$13.8 billion in 1995 [8]. The most widely
accepted measure for quantifying risk of osteoporosis is the
amount of bone mass in the skeleton, as denoted by bone mineral
density (BMD) [9]. Since hip fracture is the most severe type of OF
and directly associated with high morbidity and mortality [10], hip
or femoral neck (FN) BMD is the most important risk phenotype
for osteoporosis.
Obesity and osteoporosis are closely related diseases [11].
Adipocytes and osteoblasts (the bone formation cell) share the
same progenitor, bone marrow mesenchymal stem cells, and can
transdifferentiate into each other [12]. Adipocytes secrete factors
important to bone remodeling, such as the estrogen synthesis
enzyme, aromatase, and proinflammatory cytokines [12]. In-
creased bone marrow fat was found in osteoporosis patients [13]
and correlation between obesity phenotypes (e.g., body weight and
BMI) and osteoporosis risk phenotypes (e.g., BMD) was observed
[14–16]. Several mechanisms were identified in mouse models for
fat-bone correlations/interactions and the potential mechanistic
links between obesity and osteoporosis, for example, leptin’s
influence via the sympathetic nerve system [17,18]. However, the
extent to which these mechanisms are relevant to normal human
population is still unknown.
Since both obesity and osteoporosis have high genetic
predisposition, pleiotropic genes may exist to influence the risks
of both diseases, which was supported by studies suggesting
significant genetic correlation between the two diseases [11,19].
Recently, we conducted a bivariate whole genome linkage scan
and identified several genomic regions shared by obesity and
osteoporosis, providing further support for the existence of
pleiotropic genes for the two diseases [20]. Importantly, identifi-
cation of such pleiotropic genes in humans may offer novel insights
into the pathogenic links between obesity and osteoporosis. Such
findings, as compared to those from studies using mouse models,
may have more direct relevance to normal human population so
as to provide important targets for treatment and prevention of
both diseases. To identify such pleiotropic genes, we here
performed the first bivariate GWAS of obesity and osteoporosis
taking advantage of Affymetrix high throughput SNP genotyping
platform. Using Affymetrix 500K array, we successfully genotyped
and analyzed a total of ,380,000 SNPs in 1,000 unrelated
homogeneous Caucasians. Through bivariate association analyses,
we identified the SOX6 gene (SRY-box 6) as a potential pleiotropic
gene underlying both obesity and osteoporosis.
Results
We compared statistical power of bivariate association analyses
of two continuous traits with that of univariate association analyses
of each trait separately. According to our power analyses,
analyzing two traits simultaneously using bivariate association
approach consistently achieved higher statistical power under all
the 3 genetic models (i.e., additive, dominant, and recessive) and
different SNP effect sizes than analyzing each trait separately using
univariate association approach. For example, under the additive
model, the model we used in our real data association analysis in
this study, the power to detect a QTL of a heritability of 0.01 is
under 60% using univariate association analysis approach, as
compared with a ,80% power using bivariate association analysis
approach. (A heritability of 0.01 means that the QTL under
simulation contributes 1% variation for both traits of a bivariate
phenotype, e.g., BMI and BMD.) The detailed results are
presented in Appendix S1.
We identified two interesting SNPs in the male subjects of our
GWAS cohort, which are rs297325 and rs4756846. The two SNPs,
although not univariately associated with BMI or hip BMD at the
significance level of p=0.05, were strongly associated with BMI-
hip BMD bivariately, achieving p values at the levels of 10
26 to
10
27. The basic characteristics of our GWAS cohort are
summarized in Table 1 and the bi/univariate association results
are shown in Table 2. In the male subjects of our GWAS cohort,
the correlation coefficient between BMI and hip BMD is 0.384
(p,0.001), and that between FM and hip BMD is 0.244 (p,0.001).
The two SNPs are in the intron 1 of the SOX6 gene. According
to the analysis using the HaploView program, the two SNPs have
very weak LD (r
2,0.05) between each other.
To further confirm the relevance of our findings to obesity, we
also performed univariate analysis of FM as well as bivariate
analysis of FM-hip BMD at the two SNPs (Table 2). Again, at the
univariate level, the SNPs were not found to be associated with
FM at the significance level of p=0.05. However, at the bivariate
Table 1. Basic Characteristics of Study Subjects.
Traits GWAS cohort FHS cohort
Male (N=499) Female (N=501) Male (N=1,370) Female (N=1,985)
Age (years) 50.5 (18.9) 50.1 (17.7) 62.0 (11.4) 63.9 (12.4)
Height (cm) 177.8 (7.0) 163.8 (6.5) 174.2 (7.0) 159.7 (6.9)
Weight (kg) 89.0 (14.9) 71.2 (15.9) 86.1 (14.4) 69.4 (15.0)
BMI (kg/m
2) 28.9 (4.3) 27.3 (6.0) 28.3 (4.2) 27.2 (5.5)
Fat mass (kg) 23.5 (8.9) 26.9 (10.3) 22.8 (6.2) 27.7 (8.7)
Hip/FN BMD (g/cm
2) 1.03 (0.15) 0.91 (0.14) 0.96 (0.14) 0.84 (0.16)
Note: Presented are means (SD).
doi:10.1371/journal.pone.0006827.t001
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association with FM-hip BMD (Table 2).
The SNP, rs4756846, also showed predictive efficacy for
obesity. We stratified our male subjects in our GWAS cohort into
obese and normal groups based on the diagnostic criterion for
obesity (i.e., BMI$30 kg/m
2). In our male subjects, 146 subjects
are defined as obese and the remaining 353 are normal. According
to our analysis, for the SNP rs4756846, the non-carriers of the
minor allele, C, has an odds ratio of 1.75 (p=0.048) for obesity, as
compared to the carriers.
These two SOX6 SNPs ranked at the top in significance for
bivariate association with BMI-hip BMD in the male subjects among
all the ,380,000 SNPs examined genome-wide. The two SNPs also
ranked among the top 5 SNPs for bivariate association with FM-hip
BMD in the male subjects among all the SNPs tested genome-wide.
For readers’ information, we list in Appendix S2 the top 5 SNPs for
bivariate association with BMI-hip BMD and the top 5 SNPs for
association with FM-hip BMD. Due to the top significance achieved
by these two SNPs in our GWAS, our replication analyses in the FHS
cohort were focused only on these two SNPs.
The two SNPs were replicated in the 1,370 male subjects of the
FHS cohort. The basic characteristics of the FHS cohort are
summarized in Table 1. The two SNPs, rs297325 and rs4756846,
achieved p values of 0.03 and 0.02, respectively, for bivariate
association with BMI-FN BMD. In addition, the two SNPs
achieved p values of 0.04 and 0.08, respectively, for bivariate
association with FM-FN BMD. The detailed results are shown in
Table 3. In the male subjects of the FHS cohort, the correlation
coefficient between BMI and femoral neck (FN) BMD is 0.257
(p,0.001), and that between FM and FN BMD is 0.079
(p=0.015).
Using Fisher’s method [21], we combined the bivariate p values
achieved in the GWAS cohort with those achieved in the FHS
cohort (Table 4). Compared with rs4756846, the combined
bivariate p values at the rs297325 were more significant, which
are 3.83610
27 for bivariate association with BMI- BMD and
4.22610
27 for bivariate association with FM- BMD.
Since under univariate analysis, association of the two SOX6
SNPs with hip BMD, BMI and FM is non-significant in both the
GWAS and the FHS cohorts, we are unable to estimate if the
direction of effects for the SNPs is the same in the two cohorts.
We analyzed our GWAS cohort using software Structure 2.2
[22]. When 200 randomly selected un-linked markers were used to
cluster our subjects, under all the assigned values (i.e., 2, 3, and 4)
for the assumed number of population strata, k, all the subjects
were tightly clustered together, suggesting no population stratifi-
cation. The results are shown in Appendix S3. We further tested
the cohort for population stratification using EIGENSTRAT
software [23]. Based on genome-wide SNP information, we
estimated inflation factor (l), a measure for population stratifica-
tion, for each of the three traits (BMI, FM, and hip BMD) tested in
this study. Ideally, for a homogenous population with no
stratification the value of l should be equal or near to 1. In our
GWAS cohort, the estimated values for l for BMI, FM, and hip
BMD were 1.003, 1.007, and 1.009, respectively, which suggested
no population stratification and further confirmed the results from
the Structure 2.2 software.
Discussion
With GWAS becoming a convenient and powerful tool for
genetic study of common human diseases, an arising new
challenge is how to utilize efficiently the vast amount of
information generated in GWAS to better understand disease
mechanisms. Currently, GWAS are normally performed in a
univariate framework, which analyzes different phenotypes in
isolation even for a single study population. Such an approach
ignores the genetic correlation between and genetic co-predispo-
Table 2. Information on the SOX6 gene SNPs bivariately associated with obesity and osteoporosis phenotypes in the male
subjects of our GWAS.
SNP Position Role Allele
a MAF
b MAF
c Univariate P value Bivariate P value
BMI FM Hip BMD BMI-hip BMD FM-hip BMD
rs297325 16346170 Intron 1 C/T 0.229 0.225 0.32 0.15 0.80 6.82610
27 5.67610
27
rs4756846 16360087 Intron 1 C/T 0.119 0.144 0.07 0.11 0.12 1.47610
26 1.21610
26
Note:
aThe first allele represent the minor allele of each locus.
bMinor allele frequency calculated in our own Caucasian sample.
cMinor allele frequency reported for Caucasians in the public database of HapMap CEU.
doi:10.1371/journal.pone.0006827.t002
Table 3. Replication signals for the SOX6 gene SNPs in the male subjects of the FHS cohort.
SNP Position Role Allele
a MAF
b MAF
c Univariate P value Bivariate P value
BMI FM FN BMD BMI-FN BMD FM-FN BMD
rs297325 16346170 Intron 1 C/T 0.212 0.225 0.19 0.05 0.07 0.03 0.04
rs4756846 16360087 Intron 1 C/T 0.118 0.144 0.21 0.90 0.03 0.02 0.08
Note:
aThe first allele represent the minor allele of each locus.
bMinor allele frequency calculated in the FHS cohort.
cMinor allele frequency reported for Caucasians in the public database of HapMap CEU.
doi:10.1371/journal.pone.0006827.t003
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modern medicine. To address the above shortcomings, new
GWAS strategies, such as bivariate association approach as
adopted in the present work to study co-variation of two related
disease phenotypes, are necessary. The new strategy, with more
efficient use of GWAS data, may help identify pleiotropic genes
underlying diseases of shared genetic susceptibility and help reveal
the interconnected pathophysiological networks for a spectrum of
common human diseases of major public health importance.
With the novel multivariate approach, we here performed the
first genome-wide bivariate association analyses for obesity and
osteoporosis. Our study identified in the male subjects SOX6 as a
potential pleiotropic gene underlying both obesity and osteoporo-
sis. Two SNPs of the gene achieved bivariate association with
BMI-hip BMD and with FM-hip BMD, with the bivariate p values
ranking at the top among ,380,000 SNPs tested genome-wide
(Appendix S2). The bivariate association detected in our GWAS
was confirmed also in the male subjects from an FHS cohort
(Table 3).
In addition to the above statistical evidence, previous biological
studies on the SOX6 gene also support its dual role in both obesity
and osteoporosis. SOX6 is a member of the SOX gene family that
encodes a group of transcription factors defined by the conserved
high mobility group (HMG) DNA-binding domain [24]. As
documented in the OMIM website (http://www.ncbi.nlm.nih.
gov/entrez/dispomim.cgi?id=607257), the major function of
SOX6 is chondrogenesis and cartilage formation. The gene was
found to be expressed during mouse chondrogenesis and to
activate a chondrocyte differentiation marker, COL2A1 [25]. Null
mutations of the gene in mice caused skeletal abnormalities
through influencing size and mineralization rate of endochrondral
elements [26]. In respect to the gene’s relevance to obesity, two
recent studies identified that SOX6 plays an important role in
obesity-related insulin resistance [27,28]. The gene was found to
attenuate glucose-stimulated insulin secretion and was downreg-
ulated in the pancreatic beta-cells in hyperinsulinemic obese mice;
the gene’s downregulation may further stimulate beta-cell
proliferation and insulin secretion. The above evidence, together
with our GWAS findings, may prompt us to propose a
hypothetical mechanism for co-regulation of obesity and osteopo-
rosis, where the SOX6 gene’s effects on chondrocytes and
pancreatic beta cells may play a key role. However, this
mechanism is still speculative and needs extensive studies for final
validation.
Bivariate association analyses as adopted in this study is a
powerful approach in identifying pleiotropic genes for genetically
correlated complex diseases/traits, such as obesity and osteopo-
rosis. As shown in our statistical power analyses (Appendix S1),
association analyses in a bivariate framework are more powerful
than regular univariate association analyses for any of two
genetically correlated traits. This difference in power between
univariate and bivariate analyses is clearly reflected in our results.
As shown in Table 2, although in our GWAS none of the two
SOX6 gene SNPs achieved nominally significant p values (p,0.05)
for univariate association with BMI, FM or hip BMD, both SNPs
achieved p values of 10
26 to 10
27 for bivariate association with
BMI-hip BMD or FM-hip BMD. Of note is that the SOX6 gene
and its SNPs would not have been discovered for the significance
to obesity and osteoporosis in our GWAS if only univariate
association analyses were performed. Our study results underscore
the advantage of bivariate over univariate association approaches
in detecting pleiotropic genetic variants for complex diseases/
traits, especially given that these variants quite often have only
moderate effects to an individual phenotype/trait and hence may
be insensitive to regular univariate genetic association analysis.
In this study, we intentionally restricted our selection of study
phenotypes to those most important ones for obesity and
osteoporosis research. For osteoporosis, we chose only ‘‘hip
BMD’’ as the study phenotype since it is one of the most
frequently measured skeletal sites for assessing osteoporosis. More
importantly, hip BMD is directly relevant to risk of hip fracture,
the most severe and fatal outcome of osteoporosis. Therefore,
findings based on hip BMD may be clinically more important than
other osteoporosis phenotypes, such as spine BMD. For obesity,
we chose BMI and FM as study phenotypes due to the following
reasons. The WHO proposed BMI as a simple practical measure
for obesity. In epidemiological studies, BMI is also the most
commonly used obesity phenotype. We chose FM as another
obesity phenotype in order to corroborate findings achieved
through studying BMI since BMI alone may not always be
appropriate in defining obesity. For example, a very muscular
soldier with only 10%–15% body fat may have a BMI.25 kg/m
2
[29]. Therefore, our bivariate association analyses were focused
only on two pairs of phenotypes, BMI-hip BMD and FM-hip
BMD.
Currently, there is still no standard method to deal with the
multiple testing problem in a GWAS and hence the cut-off p value
for a significant association in a GWAS is not well defined. A
genome-wide significance threshold of p=4.2610
27 was recently
proposed by Lencz et al. [30] based on a Bayesian approach [31]
(to obtain$0.95 posterior probability of a correct inference of a
genetic association) and an estimate of a total of ,20,000 genes in
the human genome. This cut-off p value can be used as a rough
reference for the significance threshold for our study. In our
GWAS, the most significant SNP, rs297325, achieved p values
(6.82610
27 for bivariate association with BMI-hip BMD and
5.67610
27 for association with FM-hip BMD) that approach this
cut-off. More importantly, this and another SOX6 SNP,
rs4756846, ranked at top in significance (top 2 for bivariate
association with BMI-hip BMD and top 5 for association with FM-
hip BMD) among the ,380,000 SNPs tested genome-wide (see
Appendix S2). Therefore, these two SNPs were selected for
replication in the FHS cohort.
Population stratification and/or ethnic admixture can be an
important source of spurious association in genetic association
studies. However, these factors are unlikely to exist in our sample
Table 4. Combined bivariate p values of the SOX6 gene SNPs.
SNP GWAS bivariate P values FHS bivariate P values Combined bivariate P values
BMI-hip BMD FM-hip BMD BMI-FN BMD FM-FN BMD BMI-BMD FM-BMD
rs297325 6.82610
27 5.67610
27 0.03 0.04 3.83610
27 4.22610
27
rs4756846 1.47610
26 1.21610
26 0.02 0.08 5.39610
27 1.66610
26
doi:10.1371/journal.pone.0006827.t004
GWAS on Obesity & Osteoporosis
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6827to interfere with our GWAS results. Our GWAS cohort came
from an apparently homogenous US mid-west white population,
living in Omaha, Nebraska and its surrounding areas. We found
that the allele frequencies of the two significant SNPs in our
GWAS are very similar to those reported in the typical and
representative Caucasian samples used in the HapMap CEU
(Table 2) and those calculated in the FHS cohort (Table 3). In the
analyses using Structure 2.2 [22], all subjects used in our GWAS
consistently clustered together as a single group (Appendix S3),
suggesting no significant population substructure. In the analysis
using EIGENSTRAT [23], the measure for population stratifica-
tion, l, for each study phenotype (BMI, FM and hip BMD) as
inferred from genome-wide SNP information, was very close to 1,
which also suggests no stratification in our GWAS cohort. More
importantly, the association with the SOX6 gene was replicated in
an FHS cohort, a family-based study sample that is typically free
from interference of population structure. For the above reasons,
our association results are unlikely to be plagued by spurious
associations due to population admixture/stratification.
Our findings on male-specific bivariate association with BMI-
hip BMD (or FM-hip BMD) may be due to sex-specific genetic
architecture for obesity and osteoporosis. Sex-specific genetic
architecture has been found to be an important mechanism
underlying many human common diseases and complex traits.
This topic has been comprehensively reviewed in Ober et al [32].
In particular, for both obesity and osteoporosis, sex-specific genetic
basis has been suggested in many studies. Sex difference in
heritability of BMI was observed in a large sample containing
37,000 twin pairs from 8 countries [33]. QTL analyses in mice
[34,35] and linkage and association studies in humans [36–39]
also revealed sex-specific genomic regions and candidate genes
underlying obesity phenotypes. Sex-specific patterns were also
observed in genetic studies of osteoporosis. For example, both our
recent whole genome linkage scan [40] and candidate gene
association study [41] identified sex-specific genomic regions and
candidate genes for BMD. A large-scale meta-analysis for genome-
wide linkage scans of BMD involving.11,800 subjects also
suggested sex-specific genetic regulation of bone mass [42].
In summary, using a novel bivariate GWAS approach, we
identified a gene, SOX6, which appeared to be important to co-
variation of both obesity and osteoporosis risk phenotypes in male
subjects. Replication of our association findings in the FHS cohort
and the gene’s established importance in both chondrogenesis/
cartilage formation and obesity-related insulin resistance further
suggests the gene’s pleiotropic roles in both obesity and
osteoporosis. This work also serves as a methodology exploration
in GWAS, using bivariate analysis of obesity and osteoporosis
phenotypes as an example. Although some evidence suggests the
potential role of the SOX6 gene in co-variation of obesity and
osteoporosis phenotypes, the finding still needs to be replicated in
studies of a larger-scale.
Materials and Methods
Subjects
The GWAS cohort. The study was approved by the
Institutional Review Boards of Creighton University and
University of Missouri–Kansas City. Signed informed-consent
documents were obtained from all study participants before they
entered the study. A random sample containing 1,000 unrelated
Caucasians was identified and selected for this GWAS from our
established and expanding genetic repertoire currently containing
more than 6,000 subjects. All of the chosen subjects were US
Caucasians of European origin living in Omaha, Nebraska and its
surrounding areas. They were healthy subjects recruited for
genetic research of common human complex traits, such as BMD
and BMI. The detailed recruitment and exclusion criteria were
published elsewhere [43]. Generally, subjects with chronic diseases
and conditions involving vital organs (heart, lung, liver, kidney,
and brain) and severe endocrinological, metabolic, and nutritional
diseases were excluded from this study. In particular, for genetic
study of osteoporosis, subjects with diseases and conditions that
might potentially affect bone mass, structure, or metabolism were
excluded. These diseases/conditions included serious metabolic
diseases (diabetes, hypo- and hyper-parathyroidism,
hyperthyroidism, etc.), other skeletal diseases (paget disease,
osteogenesis imperfecta, rheumatoid arthritis, etc.), chronic use
of drugs affecting bone metabolism (hormone replacement
therapy, corticosteroid therapy, anti-convulsant drugs),
malnutrition conditions (such as chronic diarrhea, chronic
ulcerative colitis, etc.), and so forth. In addition, subjects taking
anti-bone-resorptive or bone anabolic agents/drugs, such as
bisphosphonates, were also excluded from this study. The
purpose of the above exclusion procedures was to minimize the
known environmental and therapeutical factors that influence or
are related to the endocrine systems/factors important to
development of bone mass and obesity, so that the effect sizes
due to genetic factors can be enhanced in our study sample for
more powerful detection of genetic variants via our study design.
BMI was calculated as body weight (in kilograms) divided by the
square of height (in meters). Weight was measured in light indoor
clothing without shoes, using a calibrated balance beam scale, and
height was measured using a calibrated stadiometer. We also
measured body fat mass (FM) using a Hologic 4500 DEXA
machine (Hologic Inc., Bedford, MA) in the study subjects. The
short-term reproducibility (coefficient of variation, CV) of BMI
and FM measurements was on average 0.2% and 1.1%,
respectively. Hip BMD values were measured also using the
DEXA machine. The CV of the DXA measurements for hip
BMD was 1.98%. The general relevant characteristics of the study
subjects were listed in Table 1.
The FHS replication cohort. To replicate our GWAS
findings, we used a sample from the FHS population, which
contains 3,355 Caucasians, including 1,370 males and 1,985
females, from 975 families. The phenotype and genotype
information of the cohort was downloaded from Framingham
SHARe (SNP Health Association Resource), accessed through
NCBI dbGaP (http://view.ncbi.nlm.nih.gov/dbgap). Appropriate
procedures have been taken for the usage of the data, which
include approval from UMKC IRB and signatures on the Data
Distribution Agreement by all the UMKC investigators who have
access to the data.
BMI, FM and femoral neck (FN) BMD information was
available for all the study subjects according to the Framingham
SHARe. The basic characteristics of the study subjects are
presented in Table 1.
Genotyping
GWAS cohort. Genomic DNA was extracted from whole
human blood using a commercial isolation kit (Gentra systems,
Minneapolis, MN, USA) following the protocols detailed in the kit.
Genotyping with the Affymetrix Mapping 250k Nsp and
Affymetrix Mapping 250k Sty arrays was performed using the
standard protocol recommended by the manufacturer.
Genotyping calls were determined from the fluorescent
intensities using the DM algorithm with a 0.33 p-value setting
[44] as well as the B-RLMM algorithm [45]. DM calls were used
for quality control while the B-RLMM calls were used for all
GWAS on Obesity & Osteoporosis
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94 samples per cluster.
In our GWAS genotyping experiment, following an Affymetrix
guideline, we set a standard for the minimum DM call rate at 93%
for a sample, considering all the SNPs in the two arrays (i.e., the
250k Nsp and 250k Sty arrays). 99% of all the subjects (i.e., 990
subjects among a total of 1,000 subjects) met this call rate
standard. The remaining 10 samples that did not meet this
standard however had one hybridized array passing or approach-
ing this call rate standard (i.e., 93% of all the SNPs in the array
were successfully called). Hence the genotype data in the array
(with the higher call rate) for these 10 samples were also kept in the
dataset for GWAS analysis. For all the 1,000 subjects, the average
DM call rate reached.95%.
The final average BRLMM call rate across the entire sample
reached the high level of 99.14%. However, out of the initial full-
set of 500,568 SNPs, we discarded 32,961 SNPs with sample call
rate,95%, another 36,965 SNPs with allele frequencies deviating
from Hardy-Weinberg equilibrium (HWE) (p,0.001) and 51,323
SNPs with minor allele frequencies (MAF),1%. Therefore, the
final SNP set maintained in the subsequent analyses contained
379,319 SNPs, yielding an average marker spacing of ,7.9 kb
throughout the human genome.
FHS replication cohort. Using the FHS cohort, we
performed in silico replication of two interesting SNPs (rs297325
and rs4756846) identified in our GWAS cohort (see details for the
SNPs in the Results section and in Table 2). Genotyping of the FHS
cohort was performed with Affymetrix 500K mapping array plus
Affymetrix 50K supplementary array. For details of the genotyping
method, please refer to Framingham SHARe at NCBI dbGaP
website (http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/
study.cgi?study_id=phs000007.v3.p2). Specifically, for both of the
two SNPs of interest, the call rate is 99.8%. The p values for HWE
test at the two SNPs are 0.22 for rs297325 and 0.86 for rs4756846,
suggesting HWE and good genotyping quality at the SNPs.
Statistical Analyses
We compared statistical power of bivariate association analyses
of two continuous traits with that of univariate association analyses
of each trait separately. Under three genetic models, i.e., additive,
dominant, and recessive, we performed power analyses using the
GEE (Generalized Estimation Equation) Package implemented in
the R environment (http://cran.r-project.org/src/contrib/De-
scriptions/geepack.html) for genotype-based bivariate association
analyses. We used ANOVA in R and performed power analyses of
genotype-based univariate association analyses. The power
analyses were based on a sample size of 500 unrelated subjects
(in consistence with our gender-specific GWAS analysis, where the
sample size is ,500). One thousand replicates were run in
simulation to calculate the power. The detailed procedures of
simulation for power calculation are presented in Appendix S1.
Bivariate GWAS analyses were performed using SAS (SAS
Institute Inc., Cary, NC), where bivariate regression analyses were
conducted to detect association between a SNP and two
phenotypes. The analyses were based on a linear model. Denote,
for an individual i , yi be a vector of a length of 2, coding the
individual’s bivariate phenotype, which can be modeled as
yi1
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where m~ m1
m2
  
is the grand mean vector, xi is the genotype score
at the locus of interest for individual i , Z~ z1z2    zn ðÞ is a vector
coding for covariates and may include other risk factors and
confounding factors, b
0s represent the corresponding effects of
covariates or the SNP under test, and ei is the random error
vector. We tested the alternative hypothesis by comparing the
likelihood of the model under the null hypothesis (SNP effects are
restricted to 0) with that under the alternative hypothesis (the SNP
effects are not 0). The likelihood ratio can convert to an F-statistic,
which follows an F-distribution under the null hypothesis. The
bivariate p value was then calculated based on the F-statistic.
We have recently published two papers that used approaches
similar to that as shown above for bivariate association analyses
[46,47].
In the FHS cohort, a family-based sample, bivariate association
analyses were performed using FBAT-GEE implemented in FBAT
(ver. 2.02) (http://biosun1.harvard.edu/,fbat/fbat.htm) [48].
FBAT-GEE generalizes univariate family-based association anal-
yses to multivariate scenarios. It can produce a X
2FBAT-GEE
statistic, which follows a chi-square distribution and its degrees of
freedom is the number of phenotypes tested. The bivariate p value
was then calculated based on the statistic.
For comparison purpose, we also calculated univariate associ-
ation with each tested phenotype using SAS (SAS Institute Inc.,
Cary, NC) in our GWAS cohort and using FBAT in the FHS
cohort. For analysis using SAS in our GWAS cohort, genotypic
association analysis was performed under the linear regression
framework, where genotype was treated as the independent
variable and the study phenotype (such as BMI) as the dependent
variable, and the phenotype was modeled as a linear function of
alternative genotypes at a certain SNP. For analysis using FBAT in
the FHS cohort, association analysis was performed by correlating
transmission of parental genotype to offspring with a phenotype.
Additive genetic model was applied in both univariate and
bivariate association analyses.
In all the above association analyses, age, age
2 and sex were
included as covariates to adjust the study phenotypes. In the
gender specific association analyses, only age and age
2 were used
as the covariates.
The linkage disequilibrium (LD) between interesting SNPs was
analyzed using the Haploview program [49] (http://www.broad.
mit.edu/mpg/haploview/) and the most recent SNP genotype
data (HapMap Data Rel 23a/phaseII Mar 08, on NCBI B36
assembly, dbSNP b126) from HapMap (www.hapmap.org).
To quantify the overall evidence of association achieved in our
GWAS and in the FHS replication cohort, Fisher’s method [21] was
used to combine the individual p values achieved in our GWAS and
FHS cohorts. The method, also known as Fisher’s combined
probability test, is a meta-analysis technique for combining the
results from independent statistical tests that have the same overall
null hypothesis (H0) [21]. The method combines p values from
different studies into one test statistic that has a chi-square distribution
using the formula X
2
2k ~{2
P k
i~1
loge pi ðÞ .T h ep value for the X
2
statistic can be extrapolated from a chi-square table using 2k ‘‘degree
of freedom’’, where k is the number of tests being combined.
To detect population stratification that may lead to spurious
association results, we used the software Structure 2.2 (http://
pritch.bsd.uchicago.edu/software.html) and EIGENSTRAT soft-
ware (http://genepath.med.harvard.edu/,reich/EIGENSTRAT.
htm) to investigate the potential substructure/stratification of our
sample. The Structure 2.2 program uses a Markov chain Monte
Carlo (MCMC) algorithm to cluster individuals into different
cryptic sub-populations on the basis of multi-locus genotype data
[22]. Using the software, we performed independent analyses under
GWAS on Obesity & Osteoporosis
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respectively, using 200 un-linked markers randomly selected
genome-wide. To confirm the results achieved through Structure
2.2, we further tested population stratification in our sample using
EIGENSTRAT software that uses principal component analysis
approach to model ancestral differences between cases and controls
[23].
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